89Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

San francisco, april 17, 2024 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of martin babler to its board of directors, effective april 13, 2024. mr. babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as president, chief executive officer and chairman of the board of alumis therapeutics.

San francisco, april 05, 2024 (globe newswire) -- 89bio, inc. (the “company” or “89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the company's common stock to eight new employees (the “inducement grants”) on april 3, 2024 (the “grant date”). the inducement grants have been granted pursuant to the company's 2023 inducement plan (the “plan”). the inducement grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with nasdaq listing rule 5635(c)(4).

–prime status is supported by positive data from the phase 2b enliven trial of pegozafermin– –phase 3 enlighten-fibrosis trial in non-cirrhotic mash (fibrosis stage f2-f3) patients is enrolling and enlighten-cirrhosis in mash patients with compensated cirrhosis (f4) is planned to initiate in the second quarter of 2024– san francisco, march 27, 2024 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the european medicines agency (ema) has granted priority medicines (prime) status to pegozafermin in patients with mash...

—co-primary endpoints in enlighten-fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic mash (fibrosis stage f2-f3) patients—

San francisco, march 08, 2024 (globe newswire) -- 89bio, inc. (the “company” or “89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 10,800 shares of the company's common stock to a new employee (the “inducement grant”) on march 6, 2024 (the “grant date”). the inducement grant has been granted pursuant to the company's 2023 inducement plan (the “plan”). the inducement grant was granted as an inducement material to this individual entering into employment with 89bio in accordance with nasdaq listing rule 5635(c)(4).

In the wake of a media giant's quarterly report, the Oracle of Omaha is again bolstering his stake in the tracking stocks with some huge insider purchases.

The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMMETRY study of efruxifermin for F4 NASH patients in Q1 of 2024; Success for Akero could mean a boost in value for 89bio. The non-alcoholic steatohepatitis market size is projected to reach $24.26 billion by 2028.

89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive with excellent phase 2 data and strong financials. 89bio's pegozafermin has shown positive results in reducing fibrosis and liver fat, and there is still potential for FGF21 molecules in the NASH field.

SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference being held on Tuesday, October 24, 2023.

89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases.

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the 2023 Cantor Global Healthcare Conference, being held in New York, NY on Tuesday, September 26, 2023 at 11:40 AM ET.

SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held in New York, NY on Monday, September 11, 2023 at 7:00 AM ET.

Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from the biotechnology company's current share price of US$16.55. The analysts believe 89bio's differentiated investigational therapeutic FGF21 analog pegozafermin (PGZ) has high potential in non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease characterized by inflammation and fibrosis of the liver that can progress to cirrhosis, liver failures, and liver cancer.